+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "CAR T Cell"

Immunotherapy in Oncology Startup Identification - Product Thumbnail Image

Immunotherapy in Oncology Startup Identification

  • Report
  • June 2020
  • 280 Pages
  • Global
Global Cancer Immunotherapy Market Analysis & Forecast to 2025 - Product Thumbnail Image

Global Cancer Immunotherapy Market Analysis & Forecast to 2025

  • Report
  • November 2020
  • 450 Pages
  • Global
From
CAR-T Therapies Market (2nd Edition), 2019-2030 - Product Thumbnail Image

CAR-T Therapies Market (2nd Edition), 2019-2030

  • Report
  • August 2019
  • 580 Pages
  • Global
From
From
CAR-T Cell Therapy Market Review - Product Thumbnail Image

CAR-T Cell Therapy Market Review

  • Report
  • December 2019
  • 59 Pages
  • Global
From
From
From
From
Loading Indicator

CAR T Cell therapy is a type of immunotherapy used to treat certain types of cancer. It is a type of gene therapy that uses a patient's own immune cells to recognize and attack cancer cells. The patient's T cells are collected and modified to express a chimeric antigen receptor (CAR) that binds to a specific antigen on the surface of the cancer cells. The modified T cells are then infused back into the patient, where they can recognize and attack the cancer cells. CAR T Cell therapy has been approved for the treatment of certain types of blood cancers, including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). It is also being studied for the treatment of other types of cancer, including solid tumors. CAR T Cell therapy is a rapidly growing field, with many companies developing and marketing products. Some of the major players in the market include Novartis, Kite Pharma, Gilead Sciences, Juno Therapeutics, and Cellectis. Show Less Read more